Sanofi could go up to $ 80 per share for Genzyme
Sanofi-Aventis could make a first offer around $ 70 per share to acquire U.S. biotech Genzyme, analysts said.
Some consider that the French pharmaceutical group may raise its offer to $ 80.
Under cover of anonymity, one analyst said that "70 dollars would be a first offer" and that "at $ 80 it remains a good deal for Sanofi.
Same story for another sector specialist who believes that $ 80 "operation creates value in three years that will follow."
Citigroup, meanwhile, said that Sanofi will likely be the only buyer of American specialist on rare diseases and will pay between 74-77 dollars per share, or 19.7 to 20.5 billion dollars (15.0 to 15 6 billion euros).
Citi analysts consider that "insofar Sanofi may be the only buyer, and that shareholders are aware that Genzyme may fall into the lower half of the range of 50-60 dollars, unless an agreement is not passed the matter will be at 74-77 dollars. "
They add that the French lab could launch a hostile bid if Genzyme resists and present its offer directly to shareholders.
The shareholder Relational Investors, Carl Icahn, who hold respectively 3.8% and 4.9% from Genzyme, could be satisfied with an offer around $ 75 since they bought at 61 and 54 dollars, says Citi.
Sanofi, an agreement would be $ 75 4% accretive in 2011 and 13% in 2013, analysts have calculated the Citi.
At Raymond James, Eric Le Berrigaud doubt that "70 dollars is sufficient.Starting at $ 70, is ready to go up to $ 80, "he notes." And at 80 dollars it is not certain whether all the guarantees of success since c is roughly the level or was action before Genzyme's production problems.
The biotech has enjoyed last year a series of production problems on its sites in the U.S., which continue to weigh on its business.
"SANOFI PREFERRED FINANCIAL LOGIC"
A fourth analyst insists that Sanofi is expected to launch its bid for Genzyme even if it does not create value for the group's objective is to increase its earnings per share.
"For the operation to bring value, it should pay less than $ 70 per share, or about 64 dollars," he says."If Sanofi launches operation beyond, is that the group favors a financial logic in the short to medium term to close down its results and not the logic of value creation."
For him, "the title Genzyme could return to $ 80 after the settlement of industrial problems, but very transient because its treatment of Gaucher's disease could soon be rivaled.
Sources familiar with the case, it said last week that Sanofi intended to send a letter to Genzyme with the terms of its offer.This offer would be like "bear hug", that is to say friendly at first but may become hostile if necessary.
The Board of Directors of Sanofi has authorized a $ 18.7 billion dollars, said last week, sources familiar with the matter. But Sanofi has financial guidelines allowing it to raise its offer, that is to say, to bring more than $ 70 per share, said a source.
The experts, anyway, that Genzyme is a suspect "white knight" to deal with Sanofi.
A spokesman for the Financial Markets Authority said that the French system which requires an initiator to declare his intentions in certain conditions if the rumors do not apply when the target is foreign.In this case, the law of the country in which the target company is applying, "she added.
The action dealt Genzyme Monday up 0.5% to 69.93 dollars in early afternoon on Wall Street. In Paris, the title Sanofi closed at 45.4 euros (1.88%).